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Introduction
Sepsis, as a systematic inflammatory response to infec-
tion, compromises a number of very complex pathophysi-
ological processes: diffuse endothelial and epithelial injury,
increased capillary permeability, impaired hemodynamics,
microvascular thrombosis, tissue ischemia, apoptosis and can
result in multiple organ dysfunction 1–4. It is one of the most
frequent reasons for intensive care hospitalization. It is esti-
mated that the mortality in severe sepsis patients ranges from
40% to 70%. Moreover, it is the second leading cause of
death among patients in non-coronary intensive care units
(ICUs) and the tenth leading cause of death overall in the
United States 5, 6. Several recent studies suggest that the
mortality rate from severe sepsis is not changed remarkably
over the last 30 years. During that time, the incidence of sep-
sis has been increasing 6. The mean hospital cost per patient
was estimated at $22,100 7. Vincent et al. 8 studied patients
admitted to ICUs all over Europe and found that ICU mor-
tality was almost doubled among patients with sepsis com-
pared to those without sepsis, 27% vs 14%, respectively. ICU
mortality rate from severe sepsis and septic shock was even
higher, 32.2% and 54.1%, respectively. These results are
from SOAP study in which our ICU (Clinic of Anesthesiol-
ogy and Intensive Therapy of the Military Medical Acad-
emy, Belgrade, Serbia) participated. The results from the
most populous country, China, showed that the overall hos-
pital mortality from severe sepsis was 48.7%. The mean hos-
pital cost was $11,390 per patient and $502 per patient per
day 9. Even if patients survive sepsis, their quality of life is
expected to be substantially reduced 5, 6.
The cornerstones for the therapy of sepsis are aggresive
fluid resuscitation, source control, and antimicrobial treat-
ment. Antimicrobial agents are one of the frequently utilized
drug classes in an ICU 5, 10. The results of previous investi-
gations showed that antibiotic treatment decreases the con-
centrations of inflammatory mediators in body fluids 11, 12.
However, in patients with sepsis the rapid clinical deteriora-
tion is often seen after the first dose of cidal antibiotics. This
phenomenon could be explained with Jarish-Herxheimer re-
action (JHR), which is a syndrome with worsening of symp-
toms immediately after antimicrobial treatment of infection.
It is caused by the production of higher inflammatory me-
diators 2. Selecting an appropriate antimicrobial in terms of
spectrum of activity is the mainstay of antimicrobial therapy.
Still, the consistent choice of correct dosage regimen (in
terms of both dose and frequency of administration) has been
shown to be at least as important for successful clinical cure
and microbiological eradication as the choice of drug 13, 14.
Empirical treatment of bacterial infections in an ICU is based
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predominantly on the identification and susceptibility of
bacteria commonly isolated in that unit 10, 15. It has been
demonstrated that inappropriate use of antibiotics causes an
enhancement of antimicrobial resistance. This contributes
significantly towards elevated health care costs and patient
morbidity and mortality 16–18. Optimized exposure to antimi-
crobials has been shown to result in improved clinical out-
comes 13.
Besides, pathophysiological changes due to systematic
inflammatory response may markedly alter pharmacokinetic
(PK) and pharmacodynamic (PD) properties of drugs 19. Due
to this dosage of antibacterial drugs in critically ill patients is
not straightforward. However, newer data suggest that anti-
biotic stewardship programs lead to the reduction in duration
of hospital stay and saving in medical expenses 17, 20.
Among numerous antibacterial agents, carbapenems,
a group of ȕ-lactam antibiotics with a broad spectrum of
activity, are considered to be the first-line empirical anti-
biotic therapy in critically ill patients. They exibit in vitro
bactericidal activity against numerous pathogens, includ-
ing Gram-positive and Gram-negative aerobes and anaer-
obes, but lack activity against Enteroccocus faecium,
methicillin-resistant Staphylococcus aureus and Stenotro-
phomonas maltophilia. Currently, most often used carbap-
enems in clinical practice are: imipenem, meropenem, er-
trapenem and doripenem. Doripenem and meropenem pos-
sess a slightly more potent anti-pseudomonal activity
compared to imipenem, while ertrapenem lacks activity
against Pseudomonas aeruginosa and Enterococcus spp.
Imipenem, meropenem and doripenem have half-lives of
approximately 1 hour, while ertrapenem displays a high
protein binding and has the half-live of approximately 4
hours, making it suitable for once-daily administration.
Imipenem is susceptible to degradation by enzyme dehy-
dropeptidase-1, and requires co-administration of ci-
lastatin. Ertrapenem is more suitable for the treatment of
community-acquired infections and outpatient intravenous
antimicrobial therapy. Imipenem and meropenem are used
in treatment of moderate to severe nosocomial and poly-
microbial infections 21–26.
Considering all of the above, the aim of this study was
to review studies with PK and PD concepts in order to get
data about the appropriate dosing regimen of carbapenems in
critically ill patients with sepsis, having into account specific
pathophysiological changes in these patients.
Antibiotic pharmacokinetic/pharmacodynamic
considerations in critically ill patients
Critically ill patients receive multiple medications from
a variety of pharmacological classes due to the life threaten-
ing illness. They are a unique population with diverse disease
processes, existing or impending multiple organ dysfunction
and altered PK and PD characteristics to which pharmaco-
therapy is added 27. PK changes can be the result of organ
dysfunction, most notably the liver and kidneys, but can also
be a consequence of the acute phase response, drug interac-
tions and therapeutic interventions 28.
Pathophysiology of sepsis in critically ill patients
The pathophysiology of sepsis is complex. Activation
of inflammatory cytokine and coagulation cascades are im-
portant features of its pathogenesis and strongly influence
pharmacokinetic properties of administered medication. Cy-
tokines have the central role in positive and negative regula-
tion of immune responses and in integrating these reactions
with other physiological systems, such as the complement
and hematopoietic systems. The effect of cytokines in vivo
varies depending on time and location. They can be classi-
fied into proinflammatory [(T helper, Th1; i.e. tumor necro-
sis factor-(TNF)-Į, interleukin-(IL)-1; anti-inflammatory
Th2 cytokines; i.e. IL-10, and Th17, different from both Th1
and Th2)]. Some possess both activities, i.e. IL-6. Circulat-
ing levels of both proinflammatory and anti-inflammatory
cytokines can be either eleveted or decreased in sepsis 29, 30.
They act by binding to specific receptors at the target cell
membrane, setting off a cascade that leads to introduction,
enhancement, or inhibition of a number of cytokine-
regulated genes in nucleus, thereby modulating cytokine-
regulated activity of cells. There is a great variability seen in
the clinical profile and outcome in patients who encounter
similar insults like trauma and/or infection. Now research is
focused on genetic determinants of the immunoinflamatory
response 31.
Pharmacokinetic changes in critically ill patients
Increase in the volume of distribution (Vd) is common
primarily due to the expansion of the extracellular fluid vol-
ume (edema). Elimination half-life can also be prolonged due
to the increased Vd. Conversely, clearance may be un-
changed 32, decreased 33, 34 or most frequently elevated 21, 35–37
as a result of augmented renal clearance, resulting in sub-
therapeutic concentrations of renally cleared antibiotics. Ede-
matous state, commonly seen in critically ill patients, may alter
the distribution of hydrophillic antibiotics (including ȕ-lactams
and aminoglycosides) and cause clinical failure of antimicro-
bial therapy in sepsis and/or trauma 15, 27, 38. As a general rule,
in critically ill patients Vd is 2.5-fold greater than normal, re-
sulting in lower plasma concentrations of antibiotics. Lack of
routine drug monitoring for most antibiotics makes it difficult
for clinicians to distinguish between insufficient antibiotic
concentrations and lack of in vivo microorganism susceptibil-
ity 39. Hydrophillic antibiotics are mainly excreted unchanged
by the kidney. This elimination will be limited in renal failure,
which is common in the critically ill. Renal failure may occur
because of trauma, multiple organ dysfunction, extensive
burns, cardiogenic or hypovolaemic shock or it may be in-
duced by use of nephrotoxic drugs 15, 27. Those patients should
receive normal antibiotic doses given less frequently, to avoid
overexposure and toxic side effects 27, 39.
Hypoalbuminemia is a frequent condition in critically
ill patients. It can be caused by increased albumin capillary
escape rate through leaky endothelium, fluid overload or
malnutrition. Hypoalbuminemia may contribute to fluid ex-
travasation and antimicrobial dilution. On the other hand, the
increase of free fraction of drug may increase Vd and clear-
Vol. 72, No. 2 VOJNOSANITETSKI PREGLED Page 177
Periý A, et al. Vojnosanit Pregl 2015; 72(2): 175–180.
ance 27. Fortunately, for the majority of antibiotics hepatic
metabolism is limited and protein binding is low enough to
make no difference to their effectiveness and there is no need
to alter doses 39.
Interstitial fluid (ISF) of tissues is the site of most in-
fections and previous results showed that antibiotic concen-
trations in ISF are 2- to 10-fold lower than plasma concen-
trations, suggesting that higher plasma concentrations may
be required to ensure target concentrations in ISF 40, 41. How-
ever, the antibiotic concentrations appear to vary between
different tissues, so the different plasma concentrations may
be required for the same bacteria depending on tissue that is
infected 38.
Antibacterial PD describes the relationship between the
drug concentration and the antibacterial effect – minimum in-
hibitory concentration (MIC). For time-dependent antibiotics,
such as ȕ-lactams, the optimal bacterial kill is achieved by the
maximum amount of time (T) over the MIC. Carbapenems re-
quire 20% and 40% of T > MIC for bacteriostatic and bacteri-
cidal activity 42. The maximum effect is achieved when the
free drug concentration above the MIC is achieved for 90–
100% of the dosing interval 15. It seems that maximum killing
effects are reached at the concentration of 4 × MIC 22 to even 6
× MIC, which may represent the target concentration to
suppress resistance emergence against P. aeruginosa 37. Based
on data obtained from the studies, imipenem is able to
maintain serum concentrations higher than or equal to the MIC
of 4 mg/L for almost 8 hours after a single intravenous
administration. Conversely, meropenem maintains T > MIC
for the whole 8-hour interval between doses only for
pathogens with the MIC equal or lower than 2 mg/L.
However, to obtain adequate concentrations for pathogens
with higher MICs (i.e.  8 for imipenem or  4 for
meropenem), it would be appropriate to increase daily doses,
to use more frequent dosing or to change the administration
method, from intermittent (a 30-minute infusion) bolus
infusion to either a prolonged (a 3-hour/or 4-hour infusion) or
continuous (a 24-hour infusion) infusion. Septic patients also
may benefit from higher doses, particularly in the first 24–48
hours of the therapy 22, 37, 43. However, even with an increased
dose, the teatment failure is of particular concern for patho-
gens with a high MIC 37.Our personal experience (unpublished data) in a study
comparing the standard 30-minute bolus infusion of 1 g of
meropenem with a 3-hour infusion in a 7 critically ill patients
with sepsis, suggests that at a 30-minute infusion time, the 1
g dose resulted in a %T > MIC of 62.5% at a MIC of 4 mg/L,
whereas a 3-hour infusion time of 1 g of meropenem resulted
in a %T > MIC of 43.7% at a MIC of 4 mg/L. Against iso-
lates with a MIC of 16 mg/L, a 30-minute infusion of 1 g of
meropenem resulted in a %T > MIC of 9.5%, whereas a 3-
hour infusion resulted in a %T > MIC of 12.5%. After the
second dose of meropenem, about 50% of patients were un-
derdosed with both fixed-dose antibiotic regimens.
Pharmacokinetic/pharmacodynamic concept
Although ȕ-lactams have traditionally been adminis-
tered by intermittent infusion, continuous or prolonged infu-
sion of those antibiotics is gaining attention because of time-
dependent PD and potential economic savings. Continuous
infusion and intermittent infusion of ȕ-lactams have similar
clinical and microbiological outcomes 44, 45, prolonged infu-
sion dosing strategy has resulted in favorable outcomes.
Meropenem 2 g administered over 3 hours every 8 hours
maintained serum concentrations and prolonged exposure at
the site of infection. The prolonged infusion regimen for pip-
eracillin-tazobactam was adopted into clinical practice in one
hospital in the United States. This prolonged infusion regi-
men means that patients receive 3.375 g of piperacillin-
tazobactam every 8 hours as a 4-hour infusion. Data suggest
that the prolonged infusion regimen achieves the targeted T
> MIC at a total daily dose that is less than total daily dose in
standard, intermittent bolus infusion regimen (3.375 g of
piperacillin-tazobactam every 6 hours). As a result, the an-
nual reduction in drug acquisition costs was $135,750 46.
Non-acquisition costs of antibiotic administration (time ex-
pended by medical and nursing staff, costs of disposable
materials and overhead cost) should be taken into account.
According to the literature, the cost-effective strategy for
administering antibiotics are infusion with syringe pumps
and volumetric pumps, used for prolonged or continuous in-
fusion 47. The dosage of antibacterial drugs in critically ill
patients is not straightforward.
Data derived from two studies comparing intermittent
versus continuos infusion of meropenem, showed that the
administration of the total daily dose of meropenem (3 g) as
a continuous infusion appears to increase the likelihood of
achieving PD targets (40% of T > MIC) and may improve
clinical outcome 48. Administration of imipenem by continu-
ous infusion requires additional work to reconstitute imi-
penem in the infusion solution due to its low solubility com-
pared to other ȕ-lactams. Additionally, imipenem and mero-
penem are the least stable ȕ-lactams. According to the pre-
scribing information, imipenem solutions are sufficiently
stable for 4 hours at 25°C, therefore it should be reconsti-
tuted every 3 hours for treatment by continuous infusion.
Although this requires additional work, it is believed that it is
potentially life-saving treatment for critically ill patients 49.
The regimen for meropenem is similar. Meropenem, recon-
stituted in normal saline solution is stable at room tempera-
ture for approximately 6 hours 50 and drug concentration can
decrease for 4% 51. It should be administered in a cold
pouch 50. The main limitation of continuous infusion is that it
ties up a line of intravascular access for the entire day, which
is not practical. Critically ill patients require multiple infu-
sions and this will require placement of other lines. Extra
lines are associated with a higher probability of a central
vascular catheter derived infection, which is associated with
higher morbidity and cost. Prolonged infusion allows 4 hours
between each 8 hours dosing interval, when other agents
could be administered through the same intravenous line.
The duration of infusion (3–4 hours) approximates the dura-
tion of coverage of the dosing interval with free drug in ex-
cess of the MIC that provides the maximal microbiological
effect 52–54. According to the literature, the prolonged infu-
sion of piperacillin-tazobactam resulted in cost savings by
reducing the dosing frequency from every 6 hours to every 8
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hours. Based on the average wholesale price, for a the treat-
ment period of 7 to 10 day for 50 patients in ICU in the
United States, $8,765 to $12,522 were saved. The approxi-
mate 4-day decrease in ICU length of stay (LOS) resulted in
cost savings of $14,000 per patient. In the same study, the
decrease in the total days of use of meropenem in ICU was
seen, because the meropenem dosing regimen did not
change, just the infusion time 55. In order to compare data,
we presented our cost in US dollars. The exchange rate of 1$
was considered to be 85 dinars, year value 2012. Based on
average wholesale price of piperacillin-tazobactam, for a
treatment period of 7 days for the dosing frequency of every
6 hours, the direct cost would be $253 per patient. The direct
cost for the treatment period of 7 days for the dosing fre-
quency of every 8 hours would be $190 per patient. It seems
that $63 per patient would be saved by reducing the dosing
frequency of piperacillin-tazobactam for the treatment period
of 7 days.
In a retrospective cohort study of critically ill patients
with infections caused by P. aeruginosa, in patients with
APACHE II score  17, the prolonged infusion of piperacil-
lin-tazobactam significantly reduced 14-day mortality com-
pared with the intermittent infusion regimen, as well as ICU
LOS 52. Meropenem administered as prolonged 3 hours infu-
sion in dose of 1 g resulted in greater T > MICs than the dose
seen after bolus infusion of the same dose of the drug. It
means that the required meropenem dosage may be reduced
by one half in patients infected with pathogens for which the
MIC < 1ȝg/mL 51–53. Another option is to decrease daily
meropenem usage by one third, giving 500 mg of mero-
penem every 6 hours. This strategy provides similar response
rates and clinical outcome and cost saving (saving of $38 per
day for medicational acquisition and supply costs) 56. Based
on average wholesale price in our country, the use of 1000
mg of meropenem every 8 hours costs $43. The use of 500
mg of meropenem every 6 hours costs $31. If we use the
same strategy and decrease daily meropenem usage by one
third, the cost saving would be $12 per day.
Based on the current knowledge on the PK and PD of
ȕ-lactams, continuous or prolonged infusion regimens are
recommended for treatment of less-susceptible P.aeruginosa
and Acinetobacter species, due to superior achievement of
target exposures in critically ill patients 27. The delay of on-
set of antibacterial activity compared with intermittent ad-
ministration can be circumvented by administration of an
initial loading dose before continuous or prolonged infu-
sion 54, 57.
Therapeutic drug monitoring of ȕ-lactams in
critically ill patients
Therapeutic drug monitoring (TDM) of antibiotics has tra-
ditionally been used to prevent toxicity. TDM is the standard of
care for aminoglycosides and glycopeptides. This strategy has
not been widely applied for ȕ-lactams because these antibiotics
have a wide therapeutic index (a ratio between the toxic dose
and the therapeutic dose of drug, used as a measure of relative
safety of a drug), but persistent mortality and increasing antibi-
otic resistance may mean that TDM of ȕ-lactams might be one
of the tools for securing favorable therapeutic outcome in criti-
cally ill patients. Measurement of drug concentrations requires
the use of high-performance liquid chromatography (HPLC).
According to the literature, new HPLC assay methods specifi-
cally targeting the needs of routine TDM application have been
developed, thus enabling simultaneous determination of ȕ-
lactams 58–61. However, HPLC is a relatively slow, costly tech-
nique that requires extensive sample preparation and clean-up
process and thus not suitable for urgent assay needs. On the
other hand, immunochemical assays techniques, which are used
for TDM of aminoglycosides and vancomycin, use the cheaper
and easy-to-use instrumentations. To date, no technique allows
simple and rapid determination of unbound ȕ-lactam plasma
concentration, which is ideally required for TDM 37.
TDM of ȕ-lactams in an ICU may be appropriate be-
cause underdosing is associated with worse clinical outcome;
PK changes are frequently large and unpredictible, even
when creatinin clearance is used to guide dosage adjustment;
suboptimal drug exposures may be important in the devel-
opment of antimicrobial resistance.
Conclusion
Determining the optimum dosing strategy for ȕ-lactams
in critically ill patients is very important. Data from various
pharmacokinetic/pharmacodynamic analysis suggest that a
clinical difference between continuous/prolonged and inter-
mittent infusion of those antibiotics still exists. Based on lit-
erature data, it seems reasonable to use the continuous or
prolonged infusion regimen of ȕ-lactams, because improved
outcome can be achieved by prolonging the T > MIC. How-
ever, until the clinical benefits are clearly confirmed by well-
designed large randomized controlled trials, ȕ-lactams are
not recommended for routine use as prolonged or continuous
infusion. Pharmacoeconomic analysis of these regimens
should also be included in future trials.
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